The Big 3

Two companies have received approved for a generic of the 2.5 mg tablet of anticoagulant rivaroxaban, which is used to reduce the risk of stroke and deep vein thrombosis.

Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.

A Columbia University dermatologist argues that physicians in her specialty should be on the lookout for metabolic syndrome and obesity — and treat it.

In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.

Findings from two recent surveys found that U.S. healthcare consumers lack much of their confidence in affordability and access to healthcare, as well as patient safety.

Patients with atopic dermatitis who had not received biologics prior to treatment with Opzelura were able to avoid biologics during the 12 months after treatment with the topical nonsteroidal, finds study at American Academy of Dermatology Association annual meeting.